Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial

DSpace Repository

Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial

Author: Zimmer, Lisa; Livingstone, Elisabeth; Hassel, Jessica C.; Fluck, Michael; Eigentler, Thomas; Loquai, Carmen; Haferkamp, Sebastian; Gutzmer, Ralf; Meier, Friedegund; Mohr, Peter; Hauschild, Axel; Schilling, Bastian; Menzer, Christian; Kieker, Felix; Dippel, Edgar; Roesch, Alexander; Simon, Jan-Christoph; Conrad, Beate; Koerner, Silvia; Windemuth-Kieselbach, Christine; Schwarz, Leonora; Garbe, Claus; Becker, Juergen C.; Schadendorf, Dirk
Tübinger Autor(en):
Eigentler, Thomas Kurt
Garbe, Claus
Published in: Lancet (2020), Bd. 395, H. 10236, S. 1558-1568
Verlagsangabe: Elsevier Science Inc
Language: English
Full text: http://dx.doi.org/10.1016/S0140-6736(20)30417-7
ISSN: 1474-547X
DDC Classifikation: 610 - Medicine and health
Dokumentart: Artikel
Show full item record

This item appears in the following Collection(s)